Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease

Fabrizio Stocchi, Mario Zappia, Valentina Dall'Armi, Jaime Kulisevsky, Paolo Lamberti, José Angel Obeso

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double-blind, double-dummy, controlled parallel group study, which compared the effectiveness of oral M/C effervescent tablets with standard oral formulation levodopa/carbidopa tablets (L/C; Sinemet) in reducing total daily OFF time. The difference of total daily OFF time (intention-to-treat population) between the two groups was not statistically significant (P = 0.07): -39.4 minutes (95%CI: -67.08 to -11.73) in M/C group vs. +3.5 minutes (95%CI: -36.19 to +43.26) in the L/C group. In the intragroup analysis, M/C significantly reduced the baseline daily OFF, which remained unchanged in the L/C group. There were no unexpected adverse events in either treatment arms, and discontinuation rates due to adverse events did not differ between the two groups [M/C: 2 patients (1.3%); L/C: 1 patient (1.4%)]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention.

Original languageEnglish
Pages (from-to)1881-1887
Number of pages7
JournalMovement Disorders
Volume25
Issue number12
DOIs
Publication statusPublished - Sep 15 2010

Fingerprint

Carbidopa
Tablets
Parkinson Disease
Antiparkinson Agents
Therapeutics
levodopa methyl ester
Population
levodopa drug combination carbidopa

Keywords

  • Levodopa methylester
  • Liquid formulation
  • Melevodopa
  • Motor fluctuations
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. / Stocchi, Fabrizio; Zappia, Mario; Dall'Armi, Valentina; Kulisevsky, Jaime; Lamberti, Paolo; Obeso, José Angel.

In: Movement Disorders, Vol. 25, No. 12, 15.09.2010, p. 1881-1887.

Research output: Contribution to journalArticle

Stocchi, Fabrizio ; Zappia, Mario ; Dall'Armi, Valentina ; Kulisevsky, Jaime ; Lamberti, Paolo ; Obeso, José Angel. / Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. In: Movement Disorders. 2010 ; Vol. 25, No. 12. pp. 1881-1887.
@article{f030838a81094f44b62981d50360bdec,
title = "Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease",
abstract = "Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double-blind, double-dummy, controlled parallel group study, which compared the effectiveness of oral M/C effervescent tablets with standard oral formulation levodopa/carbidopa tablets (L/C; Sinemet) in reducing total daily OFF time. The difference of total daily OFF time (intention-to-treat population) between the two groups was not statistically significant (P = 0.07): -39.4 minutes (95{\%}CI: -67.08 to -11.73) in M/C group vs. +3.5 minutes (95{\%}CI: -36.19 to +43.26) in the L/C group. In the intragroup analysis, M/C significantly reduced the baseline daily OFF, which remained unchanged in the L/C group. There were no unexpected adverse events in either treatment arms, and discontinuation rates due to adverse events did not differ between the two groups [M/C: 2 patients (1.3{\%}); L/C: 1 patient (1.4{\%})]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention.",
keywords = "Levodopa methylester, Liquid formulation, Melevodopa, Motor fluctuations, Parkinson's disease",
author = "Fabrizio Stocchi and Mario Zappia and Valentina Dall'Armi and Jaime Kulisevsky and Paolo Lamberti and Obeso, {Jos{\'e} Angel}",
year = "2010",
month = "9",
day = "15",
doi = "10.1002/mds.23206",
language = "English",
volume = "25",
pages = "1881--1887",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease

AU - Stocchi, Fabrizio

AU - Zappia, Mario

AU - Dall'Armi, Valentina

AU - Kulisevsky, Jaime

AU - Lamberti, Paolo

AU - Obeso, José Angel

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double-blind, double-dummy, controlled parallel group study, which compared the effectiveness of oral M/C effervescent tablets with standard oral formulation levodopa/carbidopa tablets (L/C; Sinemet) in reducing total daily OFF time. The difference of total daily OFF time (intention-to-treat population) between the two groups was not statistically significant (P = 0.07): -39.4 minutes (95%CI: -67.08 to -11.73) in M/C group vs. +3.5 minutes (95%CI: -36.19 to +43.26) in the L/C group. In the intragroup analysis, M/C significantly reduced the baseline daily OFF, which remained unchanged in the L/C group. There were no unexpected adverse events in either treatment arms, and discontinuation rates due to adverse events did not differ between the two groups [M/C: 2 patients (1.3%); L/C: 1 patient (1.4%)]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention.

AB - Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double-blind, double-dummy, controlled parallel group study, which compared the effectiveness of oral M/C effervescent tablets with standard oral formulation levodopa/carbidopa tablets (L/C; Sinemet) in reducing total daily OFF time. The difference of total daily OFF time (intention-to-treat population) between the two groups was not statistically significant (P = 0.07): -39.4 minutes (95%CI: -67.08 to -11.73) in M/C group vs. +3.5 minutes (95%CI: -36.19 to +43.26) in the L/C group. In the intragroup analysis, M/C significantly reduced the baseline daily OFF, which remained unchanged in the L/C group. There were no unexpected adverse events in either treatment arms, and discontinuation rates due to adverse events did not differ between the two groups [M/C: 2 patients (1.3%); L/C: 1 patient (1.4%)]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention.

KW - Levodopa methylester

KW - Liquid formulation

KW - Melevodopa

KW - Motor fluctuations

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=77956857267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956857267&partnerID=8YFLogxK

U2 - 10.1002/mds.23206

DO - 10.1002/mds.23206

M3 - Article

C2 - 20669296

AN - SCOPUS:77956857267

VL - 25

SP - 1881

EP - 1887

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 12

ER -